financetom
Business
financetom
/
Business
/
Electric-truck maker Nikola files for Chapter 11 bankruptcy protection
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Electric-truck maker Nikola files for Chapter 11 bankruptcy protection
Feb 19, 2025 5:23 AM

Feb 19 (Reuters) - Nikola ( NKLA ) said on Wednesday it

had filed for Chapter 11 bankruptcy protection and would pursue

a sale of all or most of its assets, after grappling with rapid

cash burn and struggling to raise funds in the past few

quarters.

The development brings a close to a challenging journey,

which included numerous leadership changes, choppy sales and a

plummeting share value.

EV firms that went public during the pandemic, promising to

revolutionize the sector, such as Fisker, Proterra and Lordstown

Motors have filed for bankruptcy in recent years as funding for

the capital-intensive operations dried up due to high interest

rates and flagging demand.

Nikola ( NKLA ) said it decided to initiate a sale process of its

assets to maximize value and ensure an orderly wind down.

The firm will continue some operations for trucks in field

and some hydrogen-fueling operations through the end of March.

The company listed assets of between $500 million and $1

billion, and estimated its liabilities were between $1 billion

and $10 billion, according to a court filing.

Phoenix, Arizona-based Nikola ( NKLA ) was founded more than a decade

ago. It went public in June 2020 and delivered its first vehicle

in the December of the following year.

Industry veteran Stephen Girsky, who was an analyst at

Morgan Stanley and an executive at General Motors ( GM ), took

over as the company's chief executive officer in August 2023. He

was then the company's fourth CEO in as many years.

It was through his special purpose acquisition company,

VectoIQ Acquisition Corp, that he took Nikola ( NKLA ) public.

Nikola ( NKLA ) ramped up production of its hydrogen-powered

fuel-cell electric trucks in 2024. But the company struggled to

raise funding and its cash balance dwindled as it continued to

lose hundreds of thousands of dollars for every vehicle sold.

Fleet operators have been hesitant to spend on setting up

charging stations and inducting electric trucks, as high

interest rates pinched budgets, hurting companies such as

Nikola ( NKLA ).

(Reporting by Akash Sriram in Bengaluru; Editing by Savio

D'Souza and Sriraj Kalluvila)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Conavi Medical Q3 Net Loss Narrows; Updates on Novasight Launch
Conavi Medical Q3 Net Loss Narrows; Updates on Novasight Launch
Aug 29, 2025
07:41 AM EDT, 08/29/2025 (MT Newswires) -- Conavi Medical ( CNVIF ) on Friday said third-quarter net loss narrowed as it cut costs, while the company plans to launch its next-generation Novasight system in the U.S. next year. For Q3, net loss decreased to $3.6 million, or $0.05 per share, from a net loss of $13 million, or $2.12 per...
NeoGenomics Says Court Decides to Invalidate Natera's Asserted Patents; Shares up Pre-Bell
NeoGenomics Says Court Decides to Invalidate Natera's Asserted Patents; Shares up Pre-Bell
Aug 29, 2025
07:49 AM EDT, 08/29/2025 (MT Newswires) -- NeoGenomics ( NEO ) said Friday that a North Carolina district court granted the company's motion for summary judgment that Natera's ( NTRA ) asserted patents are invalid for claiming ineligible subject matter. The move allows NeoGenomics ( NEO ) to continue to broadly commercialize its RaDaR ST molecular residual disease assay in...
Johnson & Johnson to Stop Clinical Development of Nipocalimab Combination Therapy for Rheumatoid Arthritis
Johnson & Johnson to Stop Clinical Development of Nipocalimab Combination Therapy for Rheumatoid Arthritis
Aug 29, 2025
07:43 AM EDT, 08/29/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Thursday that it will not proceed with the clinical development of nipocalimab in combination with an anti-tumor necrosis factor alpha therapy in rheumatoid arthritis patients with refractory disease. The company said the decision was based on the week 12 results of a phase 2a proof-of-concept study,...
iRhythm Technologies Says Trial Showed Increased Atrial Fibrillation Detection With Zio Device
iRhythm Technologies Says Trial Showed Increased Atrial Fibrillation Detection With Zio Device
Aug 29, 2025
07:49 AM EDT, 08/29/2025 (MT Newswires) -- iRhythm Technologies ( IRTC ) said Friday that a clinical trial demonstrated that its Zio long-term continuous monitoring device led to increased atrial fibrillation detection and a shorter time to diagnosis. The trial was designed to determine whether the Zio device could improve atrial fibrillation detection in people aged 65 years and older...
Copyright 2023-2026 - www.financetom.com All Rights Reserved